Navigation Links
Damon Runyon, Sohn Conference Foundations name 4 new pediatric cancer research fellows
Date:7/12/2013

New York, NY (July 12, 2013) The Damon Runyon Cancer Research Foundation has named four outstanding young scientists as recipients of the prestigious Damon Runyon-Sohn Pediatric Cancer Research Fellowship Award, committing more than $680,000 to help address a critical shortage of funding for pediatric cancer research. The Sohn Conference Foundation, dedicated to curing pediatric cancers, announced last year that it was granting $1.5 million to the Damon Runyon Cancer Research Foundation, the leading charity supporting innovative young cancer researchers, to establish the award. It provides funding to basic scientists and clinicians who conduct research with the potential to significantly impact the prevention, diagnosis or treatment of one or more pediatric cancers. Each recipient receives a three-year award ($186,000 for physician-scientists, $156,000 for basic scientists). Since 2012, this award has supported seven innovative pediatric cancer researchers.

July 2013 Damon Runyon-Sohn Fellows

Kenneth Chen, MD, with his sponsor James Amatruda, MD, PhD, at the University of Texas Southwestern Medical Center, Dallas, Texas, studies Wilms tumor, a pediatric kidney cancer that is the fourth most common childhood cancer. Wilms tumor is treated with a combination of surgery, chemotherapy, and radiation; although outcomes have dramatically improved over the decades, they remain poor for children with high-risk disease. His preliminary research has identified a subset of Wilms tumors with dysregulated expression of microRNAs, a type of short noncoding RNA that regulates protein production. He will study how this dysregulation causes cancer in children and aims to use this information to develop a novel therapeutic strategy for these tumors.

Haihua Scott Chu, PhD, with his sponsor Scott A. Armstrong, MD, PhD, at Memorial-Sloan Kettering Cancer Center, New York, New York, focuses on a promising new class of therapy that inhibits epigenetic regulators, proteins that control the expression and activity of genes through DNA sequence-independent chemical modifications. Much remains unknown about how these new drugs induce specific changes in tumors upon treatment or what their efficacy is in sustaining long-term, durable responses in patients. He plans to characterize the changes induced with the use of such inhibitors in animal and human models of leukemia. These studies may serve as a proof of principle for the broader use of epigenetic inhibitors as a part of cancer therapy.

Shuibin Lin, PhD, with his sponsor Richard Gregory, PhD, at Boston Children's Hospital, Boston, Massachusetts, is studying neuroblastoma brain cancers. Genetic amplification and aberrant expression of the oncogenes LIN28B and MYCN are associated with high-risk neuroblastoma and poor survival. Interestingly, these genes positively regulate each other and form a self-reinforcing feedback loop to drive neuroblastoma oncogenesis. His research aims to identify novel factors that interact with LIN28B/MYCN in tumor formation. He is characterizing a LIN28B-interacting long intergenic non-coding RNA (lincRNA) and will determine how the lincRNA functions to regulate neuroblastoma progression.

Amit J. Sabnis, MD, with his sponsor Trevor G. Bivona, MD, PhD, at the University of California, San Francisco, California, is exploring novel treatment options for rhabdomyosarcomas, the most common pediatric soft tissue sarcomas. These sarcomas uniquely depend on the activity of "protein chaperones" that prevent newly made proteins from forming toxic clumps. His research focuses on small molecules that inhibit one class of chaperones called HSP70s. The goal of these studies is to identify a new target for drug development to help cure this disease.

"These are some of the best young scientists working in pediatric research today, and they're at a critical juncture in their careers," says William Carroll, MD, chair of the Damon Runyon-Sohn Pediatric Cancer Fellowship Committee and Director of the New York University Cancer Institute. "They need our financial support, and we need their brilliant minds focused on curing childhood cancers. That is why this award and the work that Damon Runyon and Sohn do are so important."

Because cancer occurs less frequently in children and young adults than in the adult population, it does not receive significant funding from either the National Cancer Institute (only four percent of its budget) or the biopharmaceutical industry. As a result, there have been limited advances in recent years in treating these cancers, and fewer scientists are working in this field.

"I am inspired by Damon Runyon's dedication to finding the right projects and young scientists to fund," says Evan Sohn of the Sohn Conference Foundation. "We are all so excited to invest in these new Fellows and the cutting-edge research they're doing on behalf of children and young adults with cancer."


'/>"/>

Contact: Yung S. Lie, Ph.D.
yung.lie@damonrunyon.org
212-455-0521
Damon Runyon Cancer Research Foundation
Source:Eurekalert

Related medicine news :

1. Damon Runyon Cancer Research Foundation awards $3.3 million to 8 top young clinical investigators
2. Damon Runyon Cancer Research Foundation grants fellowship awards to 21 top young scientists
3. Sohn Conference and Damon Runyon Cancer Research Foundations name first pediatric research fellows
4. Humble, TX Dentist, Dr. Damon Huffman Now Offers Laser Periodontal Disease Treatment to Gum Disease Patients
5. Damon Runyon grants prestigious fellowship awards to 17 top young scientists
6. Elsevier organizes label-free technologies conference
7. NJ stroke researchers report advances in spatial neglect research at AAN Conference
8. Blending conference translates substance abuse research into practice
9. International conference to explore health of descendants of transatlantic slave trade
10. Dr. Yael Mosse will receive first Nachman Award in Pediatric Oncology at national conference
11. Nobel laureate to keynote international pharmaceutical conference at URI
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... On Dec. ... the Hard Rock Hotel San Diego honoring the 2016 MPN Heroes—eight individuals who have ... (MPNs) by going above and beyond the standard of care, demonstrating leadership within the ...
(Date:12/2/2016)... ... , ... Center for Autism and Related Disorders (CARD) Portland today announced plans ... (ASD) and other developmental disabilities. The group, which is being launched with the help ... opportunity to share stories and advice, seek help, and continue their education on how ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... Beverly Hills, California, will be included in the 2016 “Guide to America’s Top ... professionals based on the amalgamation of their education, experience, and professional associations. ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... veterinarian diagnostic imaging systems and the first company to offer robotic ... a Heart at their tradeshow booth # 941 for the American Association of ...
(Date:12/2/2016)... CA (PRWEB) , ... December 02, 2016 , ... ... care journeys, announced today that it has raised $6.0 million in an initial ... by Clarify Health’s conviction that patients and their caregivers can receive far better ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... -- bioLytical Laboratories, ein Weltführer bei schnellen Tests für Infektionskrankheiten, ... von Kenia eingeführt. Continue Reading ... ... (PRNewsFoto/bioLytical Laboratories) ... http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical wurde durch die Clinton ...
(Date:12/2/2016)... 2, 2016 Lianluo Smart Limited (Nasdaq: ... Company") which develops, markets and sells medical devices ... China and international markets, recently attended ... Treatment New Progress Forum, co-hosted by the Institute ... , Guangdong Provincial People,s Hospital and Cardiology ...
(Date:12/2/2016)... Research and Markets has announced the addition of Jain PharmaBiotech,s ... Companies" to their offering. ... , , Drug delivery ... value of drug delivery technologies and the anticancer drugs are difficult ... organs involved and the types of cancer as well as according ...
Breaking Medicine Technology: